secwatch.observer — SEC 8-K summary
======================================

Issuer:     LENZ Therapeutics, Inc. (LENZ)
CIK:        0001815776
Form:       8-K
Filed at:   2023-08-02T23:59:59+00:00
Accession:  0000950170-23-037141
Event type: leadership
Sentiment:  neutral
Materiality: 0.20
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Graphite Bio appoints Kimberlee Drapkin as independent director
---------------------------------------------------------------

- Board expanded from 10 to 11; Drapkin appointed effective July 28, 2023.
- Drapkin has 25+ years biotech/pharma experience; formerly CFO at Jounce Therapeutics.
- She will receive cash and equity under Director Compensation Policy, prorated from appointment.
- No arrangements or family relationships with other directors or executive officers.
- She serves on boards of Acumen Pharmaceuticals, Imugene, and Kineta.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1815776/000095017023037141/0000950170-23-037141-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1815776/000095017023037141/grph-20230728.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-037141

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer